This is an expanded access program (EAP) for Inotersen for patients with hereditary transthyretin amyloidosis (hATTR) with polyneuropathy.
Phase of Trial: Clinical Phase Unknown
Latest Information Update: 08 Nov 2017
At a glance
- Drugs Inotersen (Primary)
- Indications Amyloid polyneuropathy
- Focus Expanded access; Therapeutic Use
- 08 Nov 2017 New trial record
- 27 Oct 2017 According to Ionis Pharmaceuticals media release, the expanded access program (EAP) is palnned to initiate in recent coming months.